Hesperidin exhibits in vitro and in vivo antitumor effects in human osteosarcoma MG-63 cells and xenograft mouse models via inhibition of cell migration and invasion, cell cycle arrest and induction of mitochondrial-mediated apoptosis

GUANG-YU DU, SHENG-WEI HE, LU ZHANG, CHUAN-XIU SUN, LI-DONG MI and ZUE-GANG SUN

Department of Bone Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China

Received July 31, 2016; Accepted July 17, 2018

DOI: 10.3892/ol.2018.9439

Abstract. The objective of the present study was to investigate the anticancer properties of hesperidin against human osteosarcoma MG-63 cells. Its effects on apoptosis, cell migration, cell invasion and cell cycle arrest, and its effects on tumor volume and weight were also evaluated in the present study. MTS assay was used to study the cytotoxic effects of the compound on cell viability. Effects on apoptosis and cell cycle arrest were evaluated by flow cytometry. In vitro wound healing assay and Matrigel assay were performed to study the effects of hesperidin on cell migration and cell invasion, respectively. Hesperidin exerted dose-dependent and time-dependent growth inhibitory effects on cervical cancer cells with IC50 values of 33.5, 23.8 and 17.6 µM, respectively, at 24, 48 and 72 h time intervals. Hesperidin led to early and late apoptosis induction in these cells. Hesperidin-treated cells also led to G2/M phase cell cycle arrest, which exhibited strong dose-dependence. Hesperidin treatment also led to inhibition of cell migration and invasion.

Introduction

Osteosarcoma is a cancerous tumor affecting the bones of children and adolescents. This type of tumor is a highly aggressive malignant tumor arising from the primitive transformed cells of mesenchymal origin. Osteosarcoma preferentially targets metaphyseal regions of the long bone and, as such, the distal femur and proximal tibia account for approximately half of all osteosarcoma cases. Osteosarcoma is a deadly malignant neoplasm and mainly metastasizes to the lungs. The majority of patients with osteosarcoma are between the ages of 15 and 30 years. More than 400 cases of pediatric osteosarcoma are diagnosed in the USA each year according to a 2005 study (1-3). According to a previous study, the incidence of osteosarcoma is higher in China and Japan than in the USA (4). Osteosarcoma treatment consists of multidrug chemotherapy along with surgical resection of all regions of tumor. In cases of localized osteosarcoma, the survival rate is >70%, but for the remainder of the patients with disease recurrence, this treatment does not last long and only provides temporary relief (5,6). Numerous studies have been published that reveal the requirement of surgical remission for longstanding survival of osteosarcoma following disease recurrence (4-6). The various chemotherapeutic agents used for the treatment of osteosarcoma include cisplatin, doxorubicin, high-dose methotrexate, leucovorin and ifosfamide, or their combination. For patients with osteosarcoma, chemotherapy treatment has increased survival from 11% with surgical resection alone in the 1960s, to 70% by the mid-1980s. Despite recent advances in chemotherapy and surgical resection methods, the optimal treatment approach for osteosarcoma remains a challenge. Metastatic osteosarcoma cells have certain explicit features that make them less susceptible to conventional chemotherapeutic drugs, including high-dose methotrexate, adriamycin or cisplatin. However, these drugs may easily target primary non-metastatic osteosarcoma cells (7,8). Therefore, there is a requirement for the treatment of recurrent and metastatic osteosarcoma.

Naturally occurring chemical compounds have always served significant roles in the drug discovery process, particularly anticancer drugs during the past 30-40 years (9). Natural products, and their synthetic or semisynthetic derivatives, are currently used as lead compounds or templates for the design and development of novel and effective anticancer agents (9). There is compelling evidence that flavonoids serve crucial roles in cancer chemotherapy and chemoprevention. Flavonoids have been revealed to interact with various types of genes and enzymes, indicating their diverse molecular mechanisms of action. The various mechanisms of action of flavonoids include inactivation of different carcinogens, antiproliferative effects,
cell cycle arrest, apoptosis induction via both intrinsic and extrinsic pathways, suppression of angiogenesis, antioxidative tendency and reversal of multidrug resistance (10-13).

Materials and methods

Chemicals and other reagents. Hesperidin (purity >98%; determined by high-performance liquid chromatography) and MTT were obtained from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). Annexin V-FITC and propidium iodide were purchased from Wuhan Boster Biological Technology Ltd. (Wuhan, China). Dulbecco's modified Eagle's medium (DMEM) and RPMI-1640 medium were purchased from HyClone (GE Healthcare, Chicago, IL, USA). Fetal bovine serum (FBS), penicillin and streptomycin were purchased from Tianjin HaoYang Biological Manufacture Co., Ltd. (Tianjin, China). Horseradish peroxidase-labeled anti-mouse and anti-rabbit secondary antibodies and all other antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Cell culture plastic ware was purchased from BD Biosciences (San Jose, CA, USA).

Cell lines and cell culture conditions. The human osteosarcoma MG-63 cell line was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA) and maintained in DMEM with l-glutamine supplemented with 10% FBS, and 1.5% penicillin and streptomycin. The MG-63 cells were cultured in a highly humidified atmosphere with 5% CO₂ at 37°C.

MTS assay for cell viability. The cell cytotoxicity induced by hesperidin was evaluated by MTS assay, which is a CellTiter 96 Aqueous One Solution Cell Proliferation Assay. The wells of the 96-well plate were seeded with 2x10⁴ human osteosarcoma MG-63 cells per well, incubated overnight and then treated with increasing doses (0, 5, 25, 50, 100, 150 and 200 µM) of hesperidin for different time intervals. Following incubation for different time intervals, MTS solution was added to the cells according to the manufacturer’s protocol and then absorbance was measured at 490 nm using an ELISA plate reader (ELX 800; Bio-Tek Instruments, Inc., Winooski, VT, USA).

Annexin V binding assay/apoptosis quantification. To demonstrate and quantify the cells undergoing apoptosis, an Annexin V binding assay was performed using flow cytometry. Briefly, cancer MG-63 cells were treated with the increasing doses (0, 5, 50 and 150 µM) of hesperidin for 48 h, and then treated and untreated cells were harvested by trypsinization. Harvested cells were then incubated with Annexin V-FITC (25 ng/ml) and PI (25 µg/ml; BD Biosciences), at room temperature for 30 min in the dark, and observed using a FACS Calibur flow cytometer (BD Biosciences) taking a minimum of 15,000 cells in each sample and analyzed with Cell Quest 3.3 software (BD Biosciences).

Cell cycle phase distribution assay using flow cytometry. The effect of hesperidin on the cell cycle phase distribution in human osteosarcoma MG-63 cells was evaluated by flow cytometry using propidium iodide as a DNA staining agent. In brief, MG-63 cells at a density of 2x10⁵ cells/ml were seeded in 60-mm culture dishes containing 1% FBS. Following overnight incubation, the cells were treated with the increasing doses (0, 5, 50 and 150 µM) of hesperidin for 48 h. Subsequent to hesperidin treatment, cells were first harvested and then fixed with 70% ice-cold ethanol at 4°C overnight. The cells were then treated with RNase A (25 µg/ml; Bio-Rad Laboratories, Inc., Hercules, CA, USA), stained with 25 µg/ml propidium iodide (PI), and then observed using a flow cytometer (FACSCalibur; BD Biosciences).

In vitro wound healing assay for cell migration. The wound-healing assay was performed as previously described (14). In brief, MG-63 cells at a density of 2x10⁵ cells/ml were seeded in a 6-well plate and incubated to acquire a 100% monolayer of confluent cells. Following starvation of cells for 16 h, a 100 µl pipette was used to make a straight cell-free wound in the wells. Following washing of each well with PBS twice, the cells were treated with varying doses (0, 5, 50 and 150 µM) of hesperidin for 48 h at 37°C. The cells were then fixed and stained with 5.5% ethanol containing 1.5% crystal violet dye for 30 min at room temperature. Next, using an inverted light microscope (x200; Nikon Corporation, Tokyo, Japan), randomly selected fields were photographed and the fraction of cells that migrated into the scratched area was measured.

Invasion assay to study effects on cell invasion. The effects of hesperidin on cancer cell invasion were studied with a Matrigel assay using a Transwell chamber coated with polyvinylpyrrolidone-free polycarbonate filter (6-mm pore size). MG-63 cells at a density of 2x10⁵ cells/ml were pre-incubated with different doses of hesperidin for 30 min at 25°C. RPMI-1640 medium containing hesperidin-treated (0, 5, 50 and 150 µM) cells was seeded into the upper chamber wells. Complete DMEM was placed into the lower chamber. Following incubation for 48 h, the filter was fixed and stained with 3% ethanol containing 0.3% crystal violet (Merck KGaA, Darmstadt, Germany) for 20 min at 25°C. The stained cells were counted under a light microscope. The number of invaded cells in 6 randomly selected microscopic fields (magnification, x200) per membrane was counted.

Scanning electron microscopy (SEM) assay. In brief, human osteosarcoma MG-63 cells were seeded at a density of 2x10⁴ cells/well and were covered with 2 ml RPMI-1640 medium. Two 12-well plates were used and clean cover slips were kept at the bottom of the two plates. The plates containing cells were incubated for 12 h and then different doses (0, 5, 50 and 150 µM) of hesperidin were added into each well for 60 min. Following supernatant removal, 2 ml formalin solution (Sigma-Aldrich; Merck KGaA) was inserted into each well. The cells were then fixed using formaldehyde (10%) at 45°C for 30 min and all coverslips were soaked in 3.5% tannic acid for 24 h. The cells were then counter-fixed with 2.5% osmium tetroxide solution for 4 h, after which cells were dehydrated in ethanol and then dried using a point dryer. Finally, the cells on the coverslips were coated with gold in an ionc sputter coater (Bal-Tec Corporation, Canonsburg, PA, USA) and analyzed using a scanning electron microscope (x200; Hitachi Ltd., Tokyo, Japan).
Western blot analysis. As hesperidin targets certain key apoptotic protein signaling pathways, western blot analysis was used. In brief, human osteosarcoma MG-63 cells were seeded in a 16-cm plate for 24 h. Subsequently, the RPMI-1640 medium was removed and replaced with fresh medium. The cells were then treated at 37°C with increasing doses (0, 5, 50 and 150 µM) of hesperidin followed by 48 h incubation time. Following medium removal, the cells were washed with PBS twice prior to detaching cells and lysing in radioimmunoprecipitation assay buffer (Cell Signaling Technology, Inc.) and protease inhibitor for 30 min. Following centrifugation (8,000 x g) at 4°C for 15 min, the protein content was estimated using the bicinchoninic acid method. The protein lysates (10 µg/lane) were separated by 10% SDS-PAGE and blotted onto nitrocellulose membranes (EMD Millipore, Billerica, MA, USA). Each membrane was blocked with 5% skimmed milk at room temperature overnight, and then incubated with the designated primary antibodies overnight at 4°C.

In vivo antitumor studies on mice xenograft model. A nude xenograft mouse model was used to study the in vivo antitumor effects of hesperidin. For this purpose, male BALB/c nude mice that were 8 weeks old and weighed 18-24 g were obtained from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). A total of 30 mice were maintained with ad libitum water and food with a 12 h light and 12 h dark cycle in an animal care facility and according to animal welfare regulations and protocols approved by The Second Affiliated Hospital of Dalian Medical University (Dalian, China). Human osteosarcoma MG-63 cells at a density of 2x10^5 cells/mice were subcutaneously injected into the nude mice via the right axilla to induce the development of tumors. Five groups were created with 6 mice in each group, and the control group mice were treated with equivalent amounts of PBS, while the other four groups were treated with 5, 20, 40 and 80 mg/kg of hesperidin, respectively. Following treatment, the mice were sacrificed after 14 days, and the tumor weight and volume were measured for each mouse. Tumor volume was calculated using the following formula: V=(L x W x W)/2, where V is tumor volume, W is tumor width and L is tumor length.

Statistical analysis. All results are presented as the mean ± standard error of the mean from at least three independent experiments. The differences between groups were analyzed by one-way analysis of variance followed by Tukey's test, and P<0.05 was considered to indicate a statistically significant difference.

Results

Hesperidin induces potent cytotoxic effects in human osteosarcoma MG-63 cells. Hesperidin is a flavanone glycoside found in citrus fruits, the chemical structure of which is presented in Fig. 1. The cytotoxic effects of this compound against human osteosarcoma MG-63 cells were evaluated by MTS assay and are depicted in Fig. 2. The results indicated that hesperidin at increasing doses of 0, 5, 25, 50, 100, 150 and 200 µM led to time-dependent and concentration dependent cytotoxic effects in these cells. A sudden large increase in the cytotoxic effect was observed when the dose of hesperidin was increased from 50 to 100 µM. In order to assess the potency of the compound quantitatively, IC_{50} values at three different time intervals were calculated and were revealed to be 94.3, 78.6 and 63.3 µM at 24, 48 and 72 h, respectively.

Hesperidin induced early and late apoptosis in MG-63 cells. Annexin V-FITC assay, which is used to quantitatively estimate the percentage of apoptotic cells, was employed in the present study to evaluate effects of hesperidin on apoptosis induction in human osteosarcoma MG-63 cells. The results, which are presented in Fig. 3A-D, indicated that increasing doses of hesperidin resulted in the onset of apoptosis in MG-63 cells. Early and late apoptosis was induced and the percentage of apoptotic cells increased from 4.7% in untreated control cells to 17.9, 34.6 and 68.3% in 5, 50 and 150 µM hesperidin-treated cells, respectively. R1, R2, R3 and R4 represent necrotic cells, late apoptosis cells, viable cells and early apoptotic cells, respectively.

Hesperidin induces cell cycle arrest. Further experiments using flow cytometry revealed that hesperidin has the potential to disturb the normal cell cycle progression in human osteosarcoma MG-63 cells. The results of the present study, which are presented in Fig. 4, indicated that increasing doses of hesperidin led to the G2/M phase cell cycle arrest. The percentage of G2/M cells increased from 29.2% in untreated cells to 35.1, 46.3 and 72.4% in 5, 50 and 150 µM hesperidin-treated cells, respectively. This was accompanied...
DU et al: HERSPERIDIN HAS ANTITUMOR EFFECTS

by a simultaneous decrease in the G0/G1 cell population as the hesperidin concentration increased from 0 to 150 μM. The percentage of cells in different cell cycle phases was calculated with a FACS Calibur flow cytometer using Cell Quest 3.3 software (BD Biosciences).

Hesperidin leads to inhibition of cell migration in human osteosarcoma MG-63 cells. In this assay, the effects of hesperidin on the migration of MG-63 cells were evaluated using an in vitro wound healing assay. Following drug treatment, images of the number of cells migrated into the scratched area were

Figure 3. Determination of the apoptotic cell populations by Annexin V-FITC/propidium iodide staining at (A) 0, (B) 5, (C) 50 and (D) 150 μM concentrations of hesperidin. The experiments were performed in triplicate. FITC, fluorescein isothiocyanate; PI, propidium iodide.

Figure 4. Induction of G2 cell cycle arrest in MG-63 cells by hesperidin at concentrations of (A) 0, (B) 5, (C) 50 and (D) 150 μM. The experiments were performed in triplicate.
captured and the number of cells was calculated as percentage of migration. The results are presented in Fig. 5A-D, which reveal that increasing doses of hesperidin led to cell migration inhibition in a dose-dependent manner. The untreated group exhibited no signs of the cell migration inhibition, but following treatment with 5, 50 and 150 µM hesperidin, the percentage of migrated cells decreased from 94.5% in control to 24.5% in 150 µM-treated hesperidin, respectively.

Hesperidin led to inhibition of the invasion of MG-63 human osteosarcoma cells. Hesperidin not only inhibited cell migration but also led to inhibition of cell invasion. The results obtained using Matrigel assay revealed that increasing doses of hesperidin resulted in the inhibition of cell invasion in a dose-dependent manner. Fig. 6A-D demonstrate the effect of hesperidin on the cell invasion tendency of human osteosarcoma MG-63 cells.

SEM confirms apoptotic cell death. The fact that hesperidin triggers apoptosis was also confirmed by western blotting. The results of SEM revealed that hesperidin triggers apoptosis in cancer MG-63 cells in a concentration-dependent manner and apoptotic cells increased with an increase in the concentration of hesperidin (Fig. 7A-D). Furthermore, the induction of
Apoptosis in MG-63 cells was also associated with alterations in the expression of the apoptosis-related proteins. It was observed that, following Hesperidin treatment, the expression of Bcl-2 and Bcl-xl decreased while that of Bax, Bak, cyt-c and cleaved caspase-3 increased with an increase in the concentration of hesperidin (Fig. 8).

Hesperidin inhibits tumor growth in vivo. The anticancer effects of hesperidin were assessed in vivo in mouse xenograft models. The results revealed that MG-63 tumor growth was significantly suppressed by hesperidin administration, compared with that in the control group. At the end of the 2-week period of hesperidin treatment, the average tumor growth and volume in the untreated control group were considerably higher than those in the treated groups (Fig. 9A–C). The maximum tumor diameter observed in the present study was 1.7 cm. In addition, the in vivo growth inhibitory potential was concentration- and time-dependent.

Discussion

Hesperidin is a natural product and belongs to the coumarin class of compounds. Coumarins contain a benzopyrole nucleus on the basis of which they are categorized under four categories and

Figure 7. Scanning electron microscopy demonstrating induction of apoptosis by hespiridin in MG-63 cells at concentrations of (A) 0, (B) 5, (C) 50 and (D) 150 µM. The experiments were performed in triplicate.

Figure 8. Effect of hesperidin on the expression of apoptosis-related proteins at concentrations of (A) 0, (B) 5, (C) 50 and (D) 150 µM. The experiments were performed in triplicate.
therefore the compound of interest belongs to furanocoumarins. These compounds exhibit anticancer properties (9). Previously, the immunomodulatory activity and utility in the malignant melanoma properties of coumarins was reported (14). The proliferation of bladder cancer is suppressed effectively by photo-activated coumarins representing their use in clinical treatments (15). Despite their photo activity, even in the absence of UV radiation, they have revealed biological properties. Adhesion and motility of neoplastic cells were affected by some of the native coumarins the native coumarins (15). This aspect was well elucidated in the highly invasive murine melanoma cell line B16-F10 by Velasco-Velaquez et al (16). In the maintenance of proliferation and survival signals complex interactions are involved like between epidermal growth factor (EGF), ER-α and polypeptide growth factors such as IGF-I, transforming growth factor (TGF)-α and TGF-β (17). Estrogens increase the mitogenic capacity of IGF-I sensitizing the cells to IGF-I action through the augmentation of IGF-I signal In ER positive breast cancer cells (17). It has been observed that 25-30% of breast and ovarian cancer cases present poorer biological behavior (18). They are less responsive to anti-estrogens and exhibit lower ER levels; therefore, these patients develop a phenotype that is hormone resistant. Furthermore, high levels of HER-2/neu expression constitutively activate survival signals involving the PI3K/Akt pathway, which is associated with MAPK hyperactivity (19). The activation of the transductional pathways by psoralens in the target cells was not known until recently. 5-methoxypsoralen (bergapten) has demonstrated its influence on transductional pathways mainly involved in the regulation of cell survival in hormone-dependent and hormone-independent human mammary tumoral cell lines, including MCF-7 and SKBR-3 (20). Psoralen induced growth inhibition and apoptosis through the upregulation of the cyclin inhibitor, p21, waf and p53 mRNA and proteins (21). Bergapten transactivated the p53 gene promoter, through the involvement of the NF-γ nuclear transcriptional factor and the p38 MAPK activation was addressed by a molecular study (20).

The inhibition of cytochrome P450 and the reduction of the formation of the adducts of DNA induced by benzo[α]pyrene and 7,12-dimethylbenz[a]anthracene, by certain furanocoumarins and simple coumarins (22).

In brief, the present study revealed that hesperidin shows in vitro and in vivo antitumor and apoptotic effects in MG-63 human osteosarcoma cells via the mediation of cell cycle arrest, inhibition of cell migration and invasion and mitochondrial mediated apoptosis.

Acknowledgements
Not applicable.

Funding
This study was supported by The Second Affiliated Hospital of Dalian Medical University (Dalian, China).

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions
GD, LZ and CS performed all the experiments. LM and ZS collected the materials, performed statistical analysis and were involved in writing and revising the manuscript. SH approved the final manuscript and analyzed and interpreted the data.

Ethics approval and consent to participate
Ethical approval was obtained from the ethics committee of The Second Affiliated Hospital of Dalian Medical University.
Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: Current challenges and future directions. Expert Rev Anticancer Ther 6: 1075-1085, 2006.
2. Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev 32: 423-436, 2006.
3. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, LaQuaglia MP, Huvos AG and Meyers PA: Treatment of osteosarcoma at first recurrence after contemporary therapy: The memorial Sloan-Kettering cancer center experience. Cancer 104: 2214-2221, 2005.
4. Guo W, Xu W, Huvos AG, Healey JH and Feng C: Comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl) 112: 1101-1104, 1999.
5. Marin A, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441, 2004.
6. Ferguson W and Goorin AM: Current treatment of osteosarcoma. Cancer Invest 19: 292-315, 2001.
7. Luetke A, Meyers PA, Lewis A and Juergens H: Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev 40: 523-532, 2014.
8. Chou AJ, Geller DS and Gorlick R: Therapy for osteosarcoma: Where do we go from here? Paediatr Drugs 10: 315-327, 2008.
9. Mann J: Natural products in cancer chemotherapy: Past, present and future. Nat Rev Cancer 2: 143-148, 2002.
10. Middle EJ, Kandaswami C and Theoharides TC: The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev 52: 673-751, 2000.
11. Galati G, Teng S, Moridani MY, Chan TS and O’Brien PF: Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metab Drug Interact 17: 311-349, 2000.
12. Yang CS, Landau JM, Huang MT and Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 21: 381-406, 2001.